Imagine trying to keep a patient's blood sugar perfectly balanced, but only being able to take a snapshot every few hours. It's like trying to drive a car by only looking at the speedometer once every ten minutes; you'll likely overcorrect and crash. This technology provides a constant, live stream of sugar levels without needing constant blood draws, making it much safer to dose insulin.
ICU patients suffer from dangerous blood sugar fluctuations that increase mortality and hospital costs. Existing monitors for diabetics fail in the ICU, and traditional blood draws are impractical due to clotting and catheter limits.
A two-part system consisting of a disposable sensor with a one-year shelf life and a reusable monitor capable of real-time signal processing.
If you are a sensor manufacturer dealing with the failure of diabetic CGMs in high-acuity settings — this project developed a minimally invasive sensor that avoids clotting and drift. It targets a € 2 billion global market opportunity.
If you are a hospital group dealing with high mortality and costs due to poor glucose control in the ICU — this project developed a real-time monitor that 9 of 10 ICU managers are willing to pay for.
If you are an equipment provider dealing with the clinical unacceptability of multiple catheters — this project developed a minimally invasive system that provides real-time data processing for ICU physicians.
The market opportunity is estimated at € 2 billion globally, driven by 10 million ICU patients in the US and EU annually, many of whom have elevated blood sugar.
Based on available project data, GlucoSet utilizes a patented technology for glucose monitoring.
Specific pricing is not listed, but 9 of 10 ICU managers stated they are willing to pay for the product's use in a large share of their patients upon launch.
The project finalized the development of two components: a disposable sensor with a one-year lifetime and a reusable monitor, designed for CE-mark compliance and market scale-up.
The entire system was developed to be compliant with critical medical standards to achieve the CE-mark.
The project is led by a single Norwegian SME, GlucoSet AS, representing a 100% industry ratio. This lean structure indicates a highly focused commercialization effort, moving directly from technical development to market readiness without the overhead of academic partners.
Contact GlucoSet AS in Norway for licensing or partnership inquiries.
Contact us to explore integration of this glucose monitoring technology into your critical care portfolio.
